Treatments for Pulmonary Hypertension: Sitaxsentan/Ambrisentan (Endothelin Receptors)

LUNG (PULMONARY): MAIN MENU

Pulmonary Hypertension: MAIN MENU

What is PH?
Primary PH
Isolated PH
Secondary PH

Exercised Induced PH
Causes of PH
PH Disease Correlations
Symptoms

Diagnosis
Prognosis
Treatments
Research Registries

Research
Patient Support Organizations
Personal Stories

Treatments for Pulmonary Hypertension

Bosentan/Tracleer
Endothelin Receptors (Sitaxsentan/Ambrisentan)
Inhaled Prostacyclin (Ventavis, Iloprost)
Inhaled Nitric Oxide
Heart/Lung Transplants

Prostacyclin (Flolan, Epoprostenol) Warning
Sildenafil Citrate (Revatio, Viagra)
Stem Cell Transplant
Treprostinil (TYVASO)
Warfarin (Coumadin)

Treatments for Pulmonary Hypertension: Sitaxsentan/Ambrisentan (Endothelin Receptors)

Endothelin drugs benefit those with pulmonary hypertension. Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases. Donna Krupa. EurekAlert. (GEN News). 09/10/09. (Also see: Endothelin)

Bayer Schering Pharma Presents Positive Results Of Phase II Study With Riociguat. Results from the multi-center, open-label, uncontrolled phase II trial, showed that riociguat significantly improved exercise capacity from baseline values in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Medical News Today. 05/21/09. (Also see: Clinical Trials)

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Riociguat is currently being investigated in phase III clinical trials for the oral treatment of PH after promising results in phase II trials. J Mittendorf. National Institutes of Health PubMed. May 2009 (Also see: Clinical Trials)

The Effects Of Sitaxentan In Scleroderma-Associated Pulmonary Arterial Hypertension (SSc-PAH) Are Analogous To Those Seen In Idiopathic Pulmonary Arterial Hypertension (iPAH) The response to sitaxentan monotherapy over 1 year was similar between SSc-PAH and iPAH patients, despite baseline differences including worse baseline 6MWD in SSc-PAH and more SSc-PAH patients in FC II. Overall, sitaxentan was well tolerated and effective in SSc-PAH. However, patients with SSc-PAH may do better if detected early (before 6MWD is so reduced), so a high awareness from rheumatologists is paramount. J.E. Pope. SAT0218. EULAR 2008.

Sitaxsentan, a Selective Endothelin-A Receptor Antagonist, Improves Exercise Capacity in PAH Associated with CTD. Sitaxsentan 100 mg improves the 6-minute walk diagnostic in patients with PAH-CTD with a low incidence of abnormal liver function tests. J. R. Seibold. SAT0233 EULAR 2006. (Also see: Dr. J.R. Seibold)